Profile data is unavailable for this security.
About the company
Shuttle Pharmaceuticals Holdings, Inc. is a discovery and development stage specialty pharmaceutical company. The Company is focused on improving the outcomes of cancer patients treated with radiation therapy (RT). It is developing a pipeline of products designed to address cancer therapies as well as to extend to the new applications of radiation therapy. Its product candidates include Ropidoxuridine (IPdR), Ropidoxuridine and Tipracil (IPdR/TPI), SP-1-161, SP-2-225, and SP-1-303. Ropidoxuridine (IPdR) is its lead candidate radiation sensitizer for use in combination with RT to treat brain tumors (glioblastoma) and sarcomas. Ropidoxuridine and Tipracil (IPdR/TPI) is undergoing preclinical development for use as a radiation sensitizer for rectal cancers. SP-1-161 is a pre-clinical candidate lead histone deacetylase (HDAC) inhibitor, a radiation sensitizing candidate product. SP-2-225 is a pre-clinical class II b selective HDAC inhibitor that affects histone deacetylase HDAC6.
- Revenue in USD (TTM)0.00
- Net income in USD-7.20m
- Incorporated2018
- Employees8.00
- LocationShuttle Pharmaceuticals Holdings Inc401 Professional Drive, Suite 260GAITHERSBURG 20879United StatesUSA
- Phone+1 (240) 403-4212
- Fax+1 (845) 818-3588
- Websitehttps://shuttlepharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Psyence Biomedical Ltd | 0.00 | 1.52m | 2.06m | -- | -- | -- | 1.36 | -- | -0.0442 | -0.0442 | 0.00 | -0.3979 | 0.00 | -- | -- | -- | 1.13 | -- | 1.20 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -2.63 | -- | -- | -- |
Onconetix Inc | 1.46m | -53.12m | 2.21m | 12.00 | -- | -- | -- | 1.51 | -2.62 | -2.62 | 0.0723 | 1.27 | 0.0328 | 3.45 | 5.30 | 121,979.20 | -119.09 | -- | -215.11 | -- | -57.21 | -- | -3,629.24 | -- | 0.091 | -11.87 | 0.2984 | -- | -- | -- | -176.78 | -- | -- | -- |
SOHM Inc | -100.00bn | -100.00bn | 2.29m | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Scorpius Holdings Inc | 9.85m | -29.57m | 2.43m | 82.00 | -- | 0.015 | -- | 0.2471 | -183.17 | -200.56 | 53.89 | 51.92 | 0.1552 | -- | 11.08 | 120,061.60 | -49.90 | -39.37 | -59.65 | -43.18 | 64.27 | -- | -321.53 | -1,068.21 | 0.3127 | -43.94 | 0.3569 | -- | 1,789.58 | 3.84 | 1.96 | -- | 27.32 | -- |
Altamira Therapeutics Ltd | 186.68k | -2.10m | 2.52m | 10.00 | -- | -- | -- | 13.52 | -27.56 | -27.56 | 0.2212 | -0.0746 | 0.0407 | 1.00 | 2.96 | 18,667.85 | -45.74 | -68.57 | -- | -117.99 | -8.39 | -- | -1,124.78 | -26,516.34 | 1.79 | -12.18 | -- | -- | -- | -- | 90.46 | -- | -- | -- |
Panacea Life Sciences Holdings Inc | 2.76m | -7.67m | 2.67m | 40.00 | -- | -- | -- | 0.9666 | -0.4554 | -0.4554 | 0.164 | -0.5255 | 0.1537 | 1.62 | 10.13 | 69,098.25 | -42.65 | -69.04 | -- | -225.03 | -139.49 | -181.62 | -277.51 | -505.41 | 0.0285 | -2.12 | 4.79 | -- | 46.59 | -- | 12.33 | -- | -- | -- |
Scisparc Ltd | 0.00 | -6.96m | 2.73m | 3.00 | -- | 7.68 | -- | -- | -1.22 | -1.51 | 0.00 | 0.0344 | 0.00 | -- | -- | 0.00 | -92.51 | -69.39 | -152.41 | -111.07 | -- | -- | -- | -527.17 | -- | -- | 0.9371 | -- | 113.73 | -- | -97.61 | -- | -- | -- |
Tonix Pharmaceuticals Holding Corp | 12.46m | -149.01m | 2.97m | 103.00 | -- | 0.0315 | -- | 0.2383 | -110.99 | -110.99 | 6.16 | 4.28 | 0.1083 | 0.8436 | -- | 120,951.50 | -129.55 | -59.46 | -157.22 | -65.92 | 21.59 | -- | -1,196.12 | -5,126.73 | 0.7181 | -- | 0.1678 | -- | -- | -- | 0.1874 | -- | 320.57 | -- |
Shuttle Pharmaceuticals Holdings Inc | 0.00 | -7.20m | 3.05m | 8.00 | -- | 0.4501 | -- | -- | -10.29 | -10.29 | 0.00 | 3.04 | 0.00 | -- | -- | 0.00 | -123.53 | -- | -147.27 | -- | -- | -- | -- | -- | -- | -4.32 | 0.5076 | -- | -- | -- | -112.71 | -- | -- | -- |
Aoxing Pharmaceutical Company Inc | 30.11m | -1.46m | 3.21m | 339.00 | -- | 0.0375 | -- | 0.1065 | -0.0192 | -0.0192 | 0.3951 | 0.2507 | 0.496 | 2.32 | 2.56 | -- | -2.41 | -14.54 | -7.06 | -35.45 | 76.19 | 68.51 | -4.85 | -37.69 | 0.7368 | 0.3387 | 0.6052 | -- | 26.88 | 37.20 | -62.49 | -- | -38.80 | -- |
Sentient Brands Holdings Inc | 0.00 | -954.07k | 3.35m | 2.00 | -- | -- | -- | -- | -0.0164 | -0.0164 | 0.00 | -0.0307 | 0.00 | 0.00 | -- | 0.00 | -460.67 | -220.36 | -- | -- | -- | 41.81 | -- | -31,451.19 | 0.0015 | -2.50 | -- | -- | -73.68 | -- | 34.98 | -- | -- | -- |
China Pharma Holdings Inc | 6.25m | -4.40m | 3.66m | 231.00 | -- | 0.4941 | -- | 0.5859 | -0.6254 | -0.6254 | 0.6379 | 0.4317 | 0.417 | 2.34 | 23.57 | 27,047.32 | -29.39 | -29.66 | -59.89 | -55.25 | -25.89 | 6.47 | -70.48 | -73.09 | 0.2449 | -21.22 | 0.3494 | -- | -13.48 | -10.68 | 22.50 | -- | -25.78 | -- |
Sunshine Biopharma Inc | 30.48m | -3.68m | 3.76m | 44.00 | -- | 0.1665 | -- | 0.1232 | -194.01 | -194.01 | 1,017.85 | 20.07 | 1.06 | 3.33 | 10.19 | 692,772.50 | -12.75 | -101.52 | -15.41 | -137.04 | 30.41 | 35.47 | -12.07 | -165.33 | 3.26 | -- | 0.00 | -- | 454.42 | -- | 83.15 | -- | 110.99 | -- |
Evoke Pharma Inc | 7.53m | -6.53m | 3.87m | 4.00 | -- | 1.45 | -- | 0.5136 | -16.23 | -16.23 | 11.24 | 3.63 | 0.7128 | 0.4307 | 4.97 | 1,881,428.00 | -61.83 | -100.48 | -136.53 | -151.10 | 96.97 | -- | -86.75 | -480.52 | 1.22 | -19.91 | 0.6523 | -- | 106.51 | -- | 5.25 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Geode Capital Management LLCas of 30 Jun 2024 | 30.82k | 0.18% |
Virtu Americas LLCas of 30 Jun 2024 | 12.74k | 0.08% |
UBS Securities LLCas of 31 Mar 2024 | 1.12k | 0.01% |
Desjardins Securities, Inc.as of 31 Mar 2024 | 500.00 | 0.00% |
Tower Research Capital LLCas of 31 Mar 2024 | 251.00 | 0.00% |
Wells Fargo Bank, NA (Private Banking)as of 31 Mar 2024 | 54.00 | 0.00% |
Renaissance Technologies LLCas of 30 Jun 2024 | 0.00 | 0.00% |